This inventor holds 3 USPTO granted patents and 3 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignee: University Health Network. Active years: 2019-2022.
Company Filing History:
Years Active: 2019-2022
Title: Innovations by Jong Bok Lee in Immunotherapy
Introduction
Jong Bok Lee is a notable inventor based in Toronto, Canada. He has made significant contributions to the field of immunotherapy, particularly in the expansion and application of double negative regulatory T cells. With a total of 3 patents, his work is paving the way for advancements in cancer treatment.
Latest Patents
One of Jong Bok Lee's latest patents is a method for the expansion of double negative regulatory T cells. This method involves culturing a population of cells with artificial antigen presenting cells, specifically targeting human CD4-CD8- regulatory T cells. Another significant patent focuses on immunotherapy for the treatment of cancer, detailing methods that utilize double negative T cells for treating chemotherapy-resistant cancers, such as recurring acute myeloid leukemia. This innovative approach includes the use of allogenic double negative T cells derived from healthy donors, which do not exhibit toxicity towards normal host tissues.
Career Highlights
Jong Bok Lee is affiliated with the University Health Network, where he continues to conduct research and develop his innovative ideas. His work is instrumental in advancing the understanding and application of T cell therapies in clinical settings.
Collaborations
Jong Bok Lee collaborates with esteemed colleagues, including Li Zhang and Dalam Ly, to further enhance the impact of his research in immunotherapy.
Conclusion
Jong Bok Lee's contributions to the field of immunotherapy through his innovative patents and collaborative efforts are making a significant impact on cancer treatment. His work exemplifies the potential of regulatory T cells in advancing medical science.